86 related articles for article (PubMed ID: 8549305)
1. In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Jones RN
Drugs; 1995; 49 Suppl 2():205-7. PubMed ID: 8549305
[No Abstract] [Full Text] [Related]
2. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Gooding BB; Jones RN
Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of E-4695, a new fluoronaphthyridine antimicrobial agent.
Mirelis B; Miró E; Navarro F; Prats G
J Antimicrob Chemother; 1994 May; 33(5):1017-23. PubMed ID: 8089047
[No Abstract] [Full Text] [Related]
4. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
6. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Fuchs PC; Barry AL; Pfaller MA; Allen SD; Gerlach EH
Antimicrob Agents Chemother; 1991 Apr; 35(4):764-6. PubMed ID: 2069384
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.
Fuchs PC; Barry AL; Brown SD; Sewell DL
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):678-82. PubMed ID: 8894580
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
Gikas A; Spyridaki I; Psaroulaki A; Kofterithis D; Tselentis Y
Antimicrob Agents Chemother; 1998 Oct; 42(10):2747-8. PubMed ID: 9756789
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Molinari G; Schito GC
Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
[No Abstract] [Full Text] [Related]
11. In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Gaillot O; Berche P
Drugs; 1995; 49 Suppl 2():200-2. PubMed ID: 8549303
[No Abstract] [Full Text] [Related]
12. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
Tali-Maamar H; Tebbal S; Rahal K
Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
[TBL] [Abstract][Full Text] [Related]
14. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance among Streptococcus pneumoniae isolated at a university hospital in eastern Tennessee.
Baddour LM; Smith EA
Clin Infect Dis; 1999 Jul; 29(1):224-5. PubMed ID: 10433604
[No Abstract] [Full Text] [Related]
16. New uses for new and old quinolones and the challenge of resistance.
Hooper DC
Clin Infect Dis; 2000 Feb; 30(2):243-54. PubMed ID: 10671323
[No Abstract] [Full Text] [Related]
17. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
18. Trovafloxacin: fourth generation fluoroquinolone.
McNabb J; Nicolau D; Quintiliani R; Nightingale C
Conn Med; 1998 Aug; 62(8):483-7. PubMed ID: 9753805
[No Abstract] [Full Text] [Related]
19. Bactericidal index: a new way to assess quinolone bactericidal activity in vitro.
Morrissey I
J Antimicrob Chemother; 1997 Jun; 39(6):713-7. PubMed ID: 9222039
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
Eiferman RA
Cornea; 2001 May; 20(4):438-9. PubMed ID: 11333340
[No Abstract] [Full Text] [Related]
[Next] [New Search]
